Equities research analysts expect Assembly Biosciences Inc (NASDAQ:ASMB) to announce earnings per share (EPS) of ($0.79) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Assembly Biosciences’ earnings. The lowest EPS estimate is ($0.92) and the highest is ($0.66). Assembly Biosciences reported earnings of ($0.67) per share during the same quarter last year, which indicates a negative year over year growth rate of 17.9%. The business is scheduled to issue its next earnings report on Thursday, March 1st.
According to Zacks, analysts expect that Assembly Biosciences will report full-year earnings of ($3.15) per share for the current fiscal year, with EPS estimates ranging from ($3.49) to ($2.95). For the next year, analysts expect that the company will post earnings of ($3.20) per share, with EPS estimates ranging from ($3.22) to ($3.18). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Assembly Biosciences.
ASMB has been the topic of a number of research reports. Zacks Investment Research upgraded Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a report on Wednesday, November 15th. Jefferies Group initiated coverage on Assembly Biosciences in a report on Wednesday, November 8th. They issued a “buy” rating and a $50.00 price objective on the stock. Chardan Capital restated a “buy” rating on shares of Assembly Biosciences in a report on Sunday, September 17th. Finally, BidaskClub upgraded Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 24th.
In other news, Director William R. Ringo sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $29.55, for a total value of $29,550.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 19.60% of the company’s stock.
Several large investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of Assembly Biosciences by 21.2% during the 2nd quarter. Vanguard Group Inc. now owns 610,916 shares of the biopharmaceutical company’s stock valued at $12,615,000 after buying an additional 107,065 shares during the period. State Street Corp purchased a new stake in shares of Assembly Biosciences during the 2nd quarter valued at about $4,234,000. Northern Trust Corp raised its holdings in shares of Assembly Biosciences by 221.2% during the 2nd quarter. Northern Trust Corp now owns 195,321 shares of the biopharmaceutical company’s stock valued at $4,033,000 after buying an additional 134,513 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Assembly Biosciences by 6.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 177,312 shares of the biopharmaceutical company’s stock valued at $5,944,000 after buying an additional 11,412 shares during the period. Finally, Lyon Street Capital LLC raised its holdings in shares of Assembly Biosciences by 9.7% during the 3rd quarter. Lyon Street Capital LLC now owns 149,443 shares of the biopharmaceutical company’s stock valued at $5,219,000 after buying an additional 13,243 shares during the period. Institutional investors and hedge funds own 61.88% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/12/04/assembly-biosciences-inc-asmb-expected-to-post-earnings-of-0-79-per-share.html.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.